A Decade of Progress. A Future of Possibility.
The Cancer Research Institute (CRI)’s 2025 Cancer Immunotherapy Insights and Impact report offers a comprehensive, data-driven look at how immunotherapy has reshaped cancer treatment – from a promising frontier to a core pillar of care. With over 150 FDA approvals since 2011 and 17 new approvals in 2024 alone, the pace of innovation is accelerating and transforming lives.
This first-of-its-kind resource maps the rise of immune-based treatments across cancer types, therapeutic classes, and delivery methods. Whether you’re a patient, researcher, policymaker, or advocate, this report delivers essential insights into how far we’ve come and where the field is headed next.
What You’ll Discover
- A decade-plus-long view of FDA immunotherapy approvals, by cancer type and therapy class
- Historic, first-time approvals in 2024: the first tumor infiltrating lymphocyte (TIL) therapy, the first T-cell receptor (TCR)-engineered therapy for solid tumors, and the first IL-15 agonists
- Real-world trends of how approved immunotherapies are being used across cancer types
